CME is the intermediates of lamivudine API,and lamivudine is 

nucleoside antiviral drugs, in vitro and experimental infection in animals the hepatitis B virus (HBV) have a strong inhibition. Lamivudine in HBV infection and normal cell metabolism within three phosphate production lamivudine, which is the active form of lamivudine, both of the HBV polymerase inhibitor, this polymerase is the substrate. Lamivudine three phosphate incorporation into viral DNA chain, blocking viral DNA synthesis. Lamivudine three phosphate do not interfere with the normal cell metabolism nucleoside, it mammalian DNA polymerase α and β weak inhibition of DNA content in mammalian cells has almost no effect. Lamivudine on mitochondrial structure and function of DNA content no obvious toxicity. For the majority of patients with hepatitis B serum HBV DNA test results show that lamivudine can rapidly inhibit the replication of HBV and its continuing effect on the entire treatment process. While serum transaminase to normal, long-term use can significantly improve liver necrosis and inflammatory changes to reduce or stop the progress of liver fibrosis

(2S.5R)-5-Cytosine-1-yl-[1,3]-oxathiolane -2-carboxylic acid menthyl ester (CME)

Molecular Formula:C18H27N3O4S

CAS No: [147027-10-9]

Pharmaceutical CME